Evaluation, in Humans, of the Correlation Between Hepatotoxicity, Neurotoxicity Induced by Oxaliplatin, and Blood Levels of HMGB1

Exclusion Criteria

• •Histology other than adenocarcinoma
• •Metastatic disease
• •History of previous treatment with oxaliplatine
• •History of systemic chemotherapy administration within 5 years prior to inclusion,
• •Patient with an non balanced progressive condition/disease (liver failure, renal failure (creatinine clearance \<30mL/min), respiratory failure, congestive heart failure, myocardial infarction in the last 6 months, etc.),
• •Patient on curative dose anticoagulant,
• •Patient with complete dihydropyrimidine dehydrogenase deficiency (Uracilemia ≥ 150 ng/ml),
• •Patient not operable for the pathology concerned,
• •Pregnant or breastfeeding woman, woman of childbearing age who has not performed a pregnancy test before the procedure,
• •Patient with legal incapacity (person deprived of liberty or under curatorship, stutorship, safeguard of justice),
• •Patient who, for psychiatric, social, family or geographical reasons, cannot be followed and/or comply with the requirements of the study,,
• •Discovery of peritoneal invasion during the peritoneal exploratory of the laparoscopy